Kristen Olvera Riemenschneider

Licensing & Collaboration Transactions

• Eli Lilly on:
• its strategic research collaboration and licensing agreement with Amplitude Therapeutics to discover and develop trans-amplifying RNA (taRNA) vaccine candidates for infectious diseases; and
• in its global strategic collaboration and licensing agreement with InduPro to discover novel oncology treatments using InduPro’s proximity-guided platform.
• AbbVie on numerous transactions including:
• its exclusive licensing arrangement with RemeGen for RC148, a novel investigational PD-1/VEGF-targeted bispecific antibody;
• its strategic option-to-license agreement with Simcere Zaiming to develop a novel trispecific antibody candidate in multiple myeloma;
• a strategic collaboration and option-to-license agreement with Gilgamesh Pharmaceuticals to develop next-generation therapies for psychiatric disorders;
• a strategic research collaboration and option to license HotSpot Therapeutics' discovery-stage IRF5 small molecule allosteric therapy for the treatment of autoimmune diseases; and
• a research collaboration and licensing agreement with Caribou Biosciences for Caribou's next-generation Cas12a CRISPR hybrid RNA-DNA genome editing and cell therapy platforms.
• Novartis on multiple transactions including:
• its global license agreement with Monte Rosa Therapeutics for VAV1-directed molecular glue degraders;
• the negotiation of license and supply agreements with Spark Therapeutics for ex-US development and commercialization of Luxturna, the first approved gene therapy for an inherited disease;
• the negotiation of an investment with Blackstone for the formation of Anthos Therapeutics, and the related license of MAAA868, an anti-coagulant, to Anthos; and
• the negotiation of supply for the EU production of Kymriah, the first CAR-T cell therapy approved by the United States Food and Drug Administration (FDA).
• Moderna on multiple agreements including:
• its collaboration with CARsgen Therapeutics for the development of a combination therapy consisting of an mRNA-based cancer vaccine and an autologous CAR-T therapy;
• a strategic collaboration and license of CytomX's Probody technology for use with Moderna's mRNA therapeutics; and
• its ten-year agreement with the State of Victoria to establish a state-of-the-art, domestic mRNA manufacturing facility at Monash University.
• AstraZeneca on:
• agreements for the funding and global distribution of the University of Oxford's COVID-19 vaccine as well as the establishment of its global manufacturing and supply chain for the vaccine, including agreements with the US Biomedical Advanced Research and Development Authority (BARDA), Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance (Gavi), the Serum Institute of India (SII) and the governments of Germany, France, Italy and the Netherlands;
• the negotiation of an agreement for the development and supply of its COVID-19 long-acting antibody under an agreement with the Biomedical Advanced Research and Development Authority (BARDA) and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; and
• the negotiation of a multi-target research collaboration with Silence Therapeutics to discover, develop and commercialize small interfering RNA (siRNA) therapeutics for the treatment of cardiovascular, renal, metabolic and respiratory diseases.
• Affimed on a strategic cooperation with Artiva Biotherapeutics for the joint development of a combination therapy in the field of immuno-oncology.
• BioCryst in its license agreement with Clearside Biomedical, Inc. to develop and commercialize BioCryst’s proprietary compound avoralstat in combination with Clearside’s proprietary drug delivery device. 
• Sanofi on a long-term research collaboration with Kymera Therapeutics to discover, develop and commercialize first-in-class protein degrader therapies for patients with immune-inflammatory diseases.
• Insmed on the negotiation of a license and collaboration agreement with AstraZeneca regarding an early-stage respiratory drug.
• Omada Health on a long-term strategic collaboration with Abbott Diabetes Care to integrate Abbott's continuous glucose monitoring (CGM) technology with Omada's professional coaching and digital care platform, aiming to create a new paradigm for people with Type 2 diabetes.
• Numerous biotechnology and pharmaceutical companies on their negotiations with HHS, BARDA, NIAID and other agencies for the government-supported research and development of COVID-19 diagnostics, therapeutics and vaccines.

M&A Transactions

• Merck on its $10 billion acquisition of Verona Pharma plc.‎
• Sanofi S.A. on its acquisition of Vigil Neuroscience, a publicly traded clinical-stage biotechnology company focused on developing novel therapies for neurodegenerative diseases.
• Insmed in the acquisition of an antibody program.
• Novartis, as global transaction counsel, on the separation and spin-off of Sandoz, its generics and biosimilars division.
• A biotechnology company on the acquisition of a solid tumor neoantigen T cell receptor R&D platform and clinical manufacturing facility, which will support the further development of its pipeline of novel cell therapies.